Skip the manufacturing step. Arm the T cells where they already are.
Aptavex pairs a T-cell-selective cell-free novel binder with an mRNA-LNP carrying a CAR construct. The binder is the address label; the LNP is the delivery vehicle; the mRNA does the engineering — all inside the patient.
Select the targeting binder
An AI-designed, engineered binder sequence is optimized to adopt a stable three-dimensional structure that specifically recognizes a T cell surface marker. Acting as a molecular address label, the binder can be manufactured by chemical synthesis instead of cell culture, enabling faster, more scalable, and cost-effective production.
Incorporated into an mRNA-LNP using a proprietary labeling technology
The binder is displayed on the surface of a lipid nanoparticle encapsulating CAR-encoding mRNA, redirecting the particle's natural tropism away from the liver and toward circulating lymphocytes.
Dose intravenously, systemically
A single infusion circulates like any biologic. The targeting ligand concentrates uptake in the intended cell population instead of relying on passive, liver-dominant distribution.
Arm T cells in place
Once internalized, the mRNA is translated transiently, and the T cell expresses a chimeric antigen receptor on its own surface — becoming a tumor-seeking effector cell without ever leaving the bloodstream.